Novel Therapeutic Approaches in the Treatment of Cancer and Inflammatory Diseases
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (17 November 2021) | Viewed by 2592
Special Issue Editors
Interests: ubiquitin proteasome; small molecule activators of p53; screening for novel biologically active molecules; functional modification of proteins; CAR-T cell immunotherapy
Interests: multi-omics medicine; precision medicine; regenerative medicine; gene and cell therapy; molecular neurobiology; molecular virology; cancer diagnostics and therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer-related inflammation is considered one of the hallmarks of cancer. Tumor growth is closely connected to inflammation, and the crosstalk between the two processes depends on certain cellular and molecular pathways. Carcinogenesis mostly results from genomic instability, proliferative abnormality, reprogramming of the stromal environment, and aberrant transition between mesenchymal and epithelial states. The concepts of cancer-associated inflammation and inflammation-driven incipient neoplasia are relatively well established, but the exact underlying mechanisms often remain elusive. This significantly limits our capabilities in relation to development of novel therapeutic approaches.
Immune-mediated inflammatory diseases represent chronic and highly disabling disorders involving inappropriate or excessive immune responses, caused or accompanied by cytokine dysregulation and acute or chronic inflammation. Examples include inflammatory bowel disease, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, multiple sclerosis, primary Sjögren’s syndrome, Crohn’s disease and various chronic inflammatory systemic diseases. A growing body of evidence suggests that many, but not all, chronic inflammatory diseases are also linked with an increased risk of cancer development.
This Special Issue aims to summarize the current knowledge about cellular and molecular mechanisms associated with tumorigenesis and inflammation, and their diverse interplay, with a primary focus on therapeutic approaches. We invite authors to contribute original manuscripts, case reports, and clinical trials, as well as reviews focused on recent advances relating to the treatment of cancer and inflammatory diseases.
Potential topics include, but are not limited to:
- Recent discoveries in the field of cancer and inflammatory diseases (including immune-mediated inflammatory diseases);
- Novel molecular biomarkers and targets;
- Therapeutic approaches based on small molecules;
- Therapeutic approaches based on gene therapies, e.g. gene editing and gene addition (including for cases with rare genetic mutations);
- Therapeutic approaches based on immune cells, like CAR-Ts, TCR-Ts, TILs, macrophages, dendritic and other cells, as well as extracellular vesicles;
- Molecular mechanisms of disease initiation and progression;
- Case reports.
Dr. Emil Bulatov
Prof. Dr. Albert Rizvanov
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- inflammatory diseases
- biomarkers
- molecular targets
- small molecule therapeutics
- gene and cell therapies
